Research programme: cyclin dependent kinase inhibitors - G1 TherapeuticsAlternative Names: Chemoprotection therapies - G1 Therapeutics; G1T-48; Pharmacoquiescence (PQ™); Radioprotection therapies - G1 Therapeutics
Latest Information Update: 02 Feb 2017
At a glance
- Originator G1 Therapeutics
- Class Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Selective estrogen receptor degraders
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Cancer; Chemoprotection; Radioprotection